Physician profile
Maofu Fu
NPI 1679749931
$1,512.39
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $324 · 2021: $141 · 2022: $17.00 · 2023: $249 · 2024: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $260 · Food and Beverage: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $259.94 |
| Food and Beverage | $206.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $454.21 | 2020-2024 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $162.57 | 2019-2024 | Opdualag |
| Janssen Biotech, INC. | $106.68 | 2020-2023 | Rybrevant |
| Incyte Corporation | $90.95 | 2023 | |
| Pfizer INC. | $74.91 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $65.77 | 2019-2024 | Lynparza, Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $52.42 | 2019-2024 | |
| Eisai INC. | $50.50 | 2019-2023 | |
| Daiichi Sankyo INC. | $44.29 | 2019-2020 | |
| Genzyme Corporation | $43.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $40.73 | 2019 | |
| Celgene Corporation | $22.41 | 2023 | Reblozyl |
| Tesaro, INC. | $22.07 | 2019 | |
| Stemline Therapeutics INC. | $21.11 | 2024 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $19.86 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $17.14 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $17.08 | 2019 | |
| Mirati Therapeutics, INC. | $16.92 | 2023 | Krazati |
| Janssen Pharmaceuticals, INC | $16.87 | 2019 | |
| Clovis Oncology, INC. | $16.69 | 2019 | |
| Lilly USA, LLC | $16.14 | 2019 | |
| Sumitomo Pharma America, INC. | $16.01 | 2024 | Orgovyx |
| Exelixis INC. | $15.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.72 | 2019 | |
| Emd Serono, INC. | $15.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.36 | 2019 | |
| Gilead Sciences, INC. | $13.17 | 2019 | |
| Verastem, INC. | $13.07 | 2019 | |
| Taiho Oncology, INC. | $12.92 | 2019 | |
| Seagen INC. | $12.44 | 2019 | |
| Array Biopharma INC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maofu Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.